177 related articles for article (PubMed ID: 10389700)
1. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.
Gionchetti P; Rizzello F; Ferrieri A; Venturi A; Brignola C; Ferretti M; Peruzzo S; Miglioli M; Campieri M
Dig Dis Sci; 1999 Jun; 44(6):1220-1. PubMed ID: 10389700
[No Abstract] [Full Text] [Related]
2. Rifaximin in the treatment of inflammatory bowel disease.
Guslandi M
World J Gastroenterol; 2011 Nov; 17(42):4643-6. PubMed ID: 22180705
[TBL] [Abstract][Full Text] [Related]
3. Rifaximin for inflammatory bowel disease.
Guslandi M
Dig Dis Sci; 2010 Jun; 55(6):1805. PubMed ID: 20428944
[No Abstract] [Full Text] [Related]
4. Rifaximin for active ulcerative colitis.
Guslandi M; Petrone MC; Testoni PA
Inflamm Bowel Dis; 2006 Apr; 12(4):335. PubMed ID: 16633057
[No Abstract] [Full Text] [Related]
5. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).
Sidhu SS; Goyal O; Mishra BP; Sood A; Chhina RS; Soni RK
Am J Gastroenterol; 2011 Feb; 106(2):307-16. PubMed ID: 21157444
[TBL] [Abstract][Full Text] [Related]
6. Rifaximin: a nonabsorbed antimicrobial as a new tool for treatment of travelers' diarrhea.
Steffen R
J Travel Med; 2001 Dec; 8(Suppl 2):S34-9. PubMed ID: 12186672
[No Abstract] [Full Text] [Related]
7. Rifaximin systemic absorption in patients with ulcerative colitis.
Rizzello F; Gionchetti P; Venturi A; Ferretti M; Peruzzo S; Raspanti X; Picard M; Canova N; Palazzini E; Campieri M
Eur J Clin Pharmacol; 1998 Mar; 54(1):91-3. PubMed ID: 9591937
[No Abstract] [Full Text] [Related]
8. Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms.
Di Stefano M; Strocchi A; Malservisi S; Veneto G; Ferrieri A; Corazza GR
Aliment Pharmacol Ther; 2000 Aug; 14(8):1001-8. PubMed ID: 10930893
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea.
DuPont HL; Jiang ZD; Okhuysen PC; Ericsson CD; de la Cabada FJ; Ke S; DuPont MW; Martinez-Sandoval F
Ann Intern Med; 2005 May; 142(10):805-12. PubMed ID: 15897530
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity and fecal concentration of rifaximin after oral administration.
Jiang ZD; Ke S; Palazzini E; Riopel L; Dupont H
Antimicrob Agents Chemother; 2000 Aug; 44(8):2205-6. PubMed ID: 10898704
[TBL] [Abstract][Full Text] [Related]
11. Use and safety of rifaximin in children with inflammatory bowel disease.
Muniyappa P; Gulati R; Mohr F; Hupertz V
J Pediatr Gastroenterol Nutr; 2009 Oct; 49(4):400-4. PubMed ID: 19668011
[TBL] [Abstract][Full Text] [Related]
12. Review--antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach.
Gionchetti P; Rizzello F; Venturi A; Ugolini F; Rossi M; Brigidi P; Johansson R; Ferrieri A; Poggioli G; Campieri M
Eur Rev Med Pharmacol Sci; 1999; 3(1):27-30. PubMed ID: 10710827
[TBL] [Abstract][Full Text] [Related]
13. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence.
Sharara AI; Aoun E; Abdul-Baki H; Mounzer R; Sidani S; Elhajj I
Am J Gastroenterol; 2006 Feb; 101(2):326-33. PubMed ID: 16454838
[TBL] [Abstract][Full Text] [Related]
14. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
15. Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease.
Chang MS; Minaya MT; Cheng J; Connor BA; Lewis SK; Green PH
Dig Dis Sci; 2011 Oct; 56(10):2939-46. PubMed ID: 21647654
[TBL] [Abstract][Full Text] [Related]
16. [Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders].
Gasztonyi B; Hunyady B
Orv Hetil; 2004 Oct; 145(43):2177-81. PubMed ID: 15575494
[TBL] [Abstract][Full Text] [Related]
17. [Role of prebiotics and probiotics in therapeutic management of cryptogenetic inflammatory bowel disease].
Marteau P; Seksik P
Gastroenterol Clin Biol; 2001 Sep; 25(2 Pt 2):C94-7. PubMed ID: 11787388
[No Abstract] [Full Text] [Related]
18. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial.
Kimer N; Pedersen JS; Busk TM; Gluud LL; Hobolth L; Krag A; Møller S; Bendtsen F;
Hepatology; 2017 Feb; 65(2):592-603. PubMed ID: 27775818
[TBL] [Abstract][Full Text] [Related]
19. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.
Sands BE; Tremaine WJ; Sandborn WJ; Rutgeerts PJ; Hanauer SB; Mayer L; Targan SR; Podolsky DK
Inflamm Bowel Dis; 2001 May; 7(2):83-8. PubMed ID: 11383595
[TBL] [Abstract][Full Text] [Related]
20. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.
Singh S; Stroud AM; Holubar SD; Sandborn WJ; Pardi DS
Cochrane Database Syst Rev; 2015 Nov; (11):CD001176. PubMed ID: 26593456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
